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Abstract
Background—Prophylaxis of hemophilia B, at present, requires multiple infusions of human
factor IX (FIX) concentrates per week. A FIX molecule with a prolonged half-life has the
potential to greatly improve convenience of, and adherence to, prophylaxis.
Objectives—The aim of our studies was to investigate the pharmacokinetic and
pharmacodynamic profile of a recombinant fusion protein linking coagulation factor IX with
albumin (rIX-FP).
Methods—Cynomolgus monkeys and hemophilia B dogs received single intravenous doses of
rIX-FP (50–500 IU kg−1). rIX-FP plasma levels were determined by an activity-based assay (dogs
only) and anti-FIX enzyme-linked immunosorbent assay methods. Additionally, activated partial
thromboplastin time (aPTT) was determined in hemophilia B dogs. Data were compared with a
direct study comparator (recombinant FIX [rFIX]) or previously published data.
Results—Terminal half-life of rIX-FP was prolonged in both species compared with FIX
reference data. In hemophilia B dogs, human FIX antigen levels remained above 0.05 IU mL−1
more than three times longer following rIX-FP (7.3 days) compared with rFIX (2.3 days), whereas
respective calculations based on activity levels confirmed observed superior profile. Prolonged
pharmacodynamics of rIX-FP was demonstrated with aPTT <60 seconds sustained around four
times longer with rIX-FP (5.9 days) than rFIX (1.5 days).
Conclusions—These studies indicate that the recombinant albumin fusion technology
successfully improves the pharmacokinetic profile of FIX. Clinical studies will test whether the
improved kinetics result in a significant half-life extension in patients with hemophilia B.
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Introduction
Hemophilia B is a blood-clotting disorder affecting approximately 1 in 25,000 human male
births [1]. It is caused by an X-linked recessive mutation resulting in a deficiency in
coagulation factor IX (FIX), a critical component of the coagulation cascade. Bleeding is
characteristic of this condition, with symptom severity dependent on the baseline FIX
activity. Management of hemophilia B, at present, requires plasma-derived (pd) or
recombinant FIX (rFIX) to be administered by intravenous (IV) infusion for both
prophylaxis and treatment.
As a result of the short half-life of current FIX treatments (17–34 hours [2–5]), patients with
severe hemophilia B, managed with prophylactic regimens, require an IV infusion 2–3 times
a week [6]. This frequency of prophylaxis may affect patient compliance and quality of life.
Consequently, there is an unmet need for FIX preparations requiring decreased frequency of
administration.
Novel FIX preparations have been developed that attempt to reduce the required infusion
frequency [7–10]. One method involves genetic fusion with albumin, a protein with a long
physiological half-life, to improve the pharmacokinetic (PK) profile of FIX. This technique
has been successful in extending the half-lives of several proteins and peptides [11–16].
Recombinant albumin fusion constructs have been developed in which human FIX
complementary DNA (cDNA) was joined to human albumin cDNA. Both proteins are
connected by a cleavable linker sequence derived from the natural activation peptide of
human FIX [10]. Thrombin generation assays demonstrated that the recombinant fusion
protein linking coagulation FIX with albumin (rIX-FP) generated thrombin levels similar to
those of wild-type rFIX, and preclinical PK studies in rodents and rabbits investigating rIX-
FP (derived from Chinese hamster ovary (CHO) cells) revealed increased in vivo recovery
(ratio of rIX-FP/rFIX, rats=1.71; rabbits=1.57), extended terminal half-life (t½) (ratio of rIX-
FP/rFIX, rats=4.70; rabbits=3.96) and increased area under the curve (AUC) versus rFIX
(ratio of rIX-FP/rFIX, rats=4.64; rabbits=7.18) [10].
The aim of our studies was to further explore the preclinical PK and pharmacodynamic (PD)
characteristics and tolerability of rIX-FP in normal cynomolgus monkeys and FIX-deficient
hemophilia B dogs.
Methods
The rIX-FP used in the studies was expressed in CHO cells with a cleavable linker sequence
between recombinant human FIX and recombinant human albumin as described by Metzner
et al [10]. The lyophilized rIX-FP was prepared by reconstitution with water for injection at
a fixed concentration of 200 IU mL−1. Visual assessment of the reconstituted rIX-FP was
performed to ensure that all contents were in solution. Animal studies were approved by the
animal care committees of the respective institutions.
Single-dose pharmacokinetics of rIX-FP in cynomolgus monkeys
The pharmacokinetics of rIX-FP were assessed in four cynomolgus monkeys (Belgrave
Services, Long Thanh District, Vietnam) following a single IV dose (bolus injection) into a
saphenous vein. Two monkeys (one male, one female) received rIX-FP at a dose of 50 IU
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kg−1; another two monkeys (one male, one female) received rIX-FP at a dose of 100 IU
kg−1. Throughout the study, twice-daily clinical observations assessed the animals for health
status and treatment reactions. Blood samples were drawn from each monkey prior to
treatment and throughout the 19-day study (5 minutes, 15 minutes, and 1, 3, 8, 23, 47, 72,
96, 120, 216, 312 and 456 hours post-dose). Citrate plasma was prepared and stored frozen
until PK and immunogenicity analyses. Validated enzyme-linked immunosorbent assay
(ELISA) techniques determined plasma concentrations of rIX-FP and anti-drug antibodies
(for immunogenicity investigations). Human FIX plasma concentrations (displayed in IU
mL−1) were evaluated using a FIX-ELISA Kit (Kordia, Leiden, Netherlands). ELISA
techniques to evaluate the presence of antibodies against human FIX and human albumin,
respectively, consisted of human FIX (CSL Behring, Marburg, Germany) or human albumin
(20%, CSL Behring) as capture reagents; a horseradish peroxidase (HRP)-conjugated
antibody against monkey immunoglobulins (Acris, Herford, Germany) was used as
detection antibody. After 216 hours, it was considered that background levels of FIX had
been reached; thus average concentrations at pre-dose as well as 216, 312 and 456 hours
post-dose were calculated for each animal to account for endogenous FIX levels. This value
was then subtracted from the measured concentration at each time point. PK parameter
estimates were derived by non-compartmental methods.
Single-dose toxicokinetics of rIX-FP in cynomolgus monkeys
Cynomolgus monkeys were used to assess the systemic tolerability and toxicokinetic (TK)
profile of rIX-FP following a single IV dose (75, 150 or 500 IU kg−1) into a cephalic vein.
Three female and three male monkeys received each dose; a control group of three males
and three females received a single dose of isotonic saline (0.9%). Throughout the study,
animals were visually assessed twice daily for health status and adverse reactions to
treatment. Blood samples were drawn from each animal before treatment, and 0.25, 1, 5, 24,
72 and 120 hours post-dose (and 240 hours post-dose from one male and female animal
from each group) followed by citrate plasma preparation and storage at around −70°C until
TK evaluation of rIX-FP plasma levels. Additional blood samples were taken from each
animal before treatment and 5 days after dosing for analysis of hematology and blood
chemistry; overnight urine samples were collected (before treatment and 5 days after dosing)
and assessed for appearance, volume, composition and sediment.
Two males and two females from each group were euthanized (with an overdose of sodium
pentobarbitone solution [200 mg mL−1]) 5 days after treatment; the remaining animals were
euthanized 10 days after dosing. Detailed necropsy procedures were completed on the day
the animals were euthanized to allow a full macroscopic evaluation of the tissues.
Plasma concentrations of human FIX (displayed in IU mL−1) were measured with a
validated ELISA method using a FIX-ELISA Kit (Kordia). Thereafter, normalized plasma
FIX concentrations (endogenous FIX concentration subtracted from the measured plasma
concentration) were used for TK analyses using non-compartmental methods. All TK
parameter estimates refer to the 5-day sampling unless otherwise stated.
Single-dose pharmacokinetics/pharmacodynamics of rIX-FP in hemophilia B dogs
Hemophilia B dogs (UNC Chapel Hill FOBRL, NC, USA) were used to assess the PK/PD
profile and immunogenicity of a single IV bolus dose (100 IU kg−1) of rIX-FP versus a
single IV dose of a marketed rFIX product (BeneFIX, Pfizer, Philadelphia, PA, USA). The
100 IU kg−1 dose was selected as it represents the upper end of the intended clinical dose
range. Three dogs received rIX-FP injected into the cephalic vein and two received rFIX.
Clinical assessments and body weights were recorded periodically throughout the treatment
and observation periods. Blood samples were drawn up to 35 days after dosing for PK/PD
Nolte et al. Page 3













(activated partial thromboplastin time [aPTT]) parameter assessments; additional samples
were used for hematology, clinical chemistry and immunogenicity investigations.
Human FIX antigen plasma concentrations were evaluated using a FIX-ELISA Kit (Kordia).
ELISA techniques to evaluate the presence of antibodies against human FIX and human
albumin, respectively, consisted of human FIX (CSL Behring) or human albumin (20%,
CSL Behring) as capture reagents; a HRP-conjugated antibody against dog IgG (Acris) was
used as detection antibody. Human FIX antigen plasma concentration data (displayed in IU
mL−1) were analyzed using a two-compartmental model. PK calculations were adjusted to a
comparable dose of 100 IU kg−1 by multiplying the measured human FIX plasma
concentrations by a ratio of nominal dose/actual dose.
Additionally, human FIX activity plasma levels were determined using an aPTT-based assay
on a Behring Coagulation Timer (Siemens Healthcare Diagnostics Products GmbH,
Marburg, Germany). FIX-deficient and standard human plasma (both for preparation of
standard curve) and aPTT reagent (silicone dioxide particles and plant phospholipids) were
obtained from Siemens Healthcare Diagnostics Products GmbH. Mixtures of dog study
plasma samples and FIX-deficient human plasma were tested in the aPTT assay and
interpreted using the standard curve. Thereafter, human FIX activity data were analyzed
using a two-compartmental model, including a background signal. PK calculations were
adjusted to a comparable dose of 100 IU kg−1 as described above.
To evaluate the presence of neutralizing antibodies, a Bethesda inhibitor assay was
performed [17]. Thereby, a dog’s plasma with a residual factor IX activity of 50% of the
normal control is defined as one “Bethesda unit” of inhibitor per mL.
The PD parameter aPTT was determined in the ST4 coagulation analyzer (Diagnostica
Stago, Asnieres, France). For aPTT determination, mixtures comprised equal portions of
partial thromboplastin (aPTT reagent), 0.025 M CaCl2 and citrated test plasma. Hematology
analyses (including platelet, white blood cell and hematocrit levels) were assessed up to 35
days after dosing using a cell counter (Heska ABC Analyzer, Grayslake, IL, USA)
calibrated for dog cells. Biochemical serum parameters (including glucose, urea and
bilirubin) were assayed automatically using a ‘Superchem’ panel (Antech Diagnostics, Cary,
NC, USA) up to 24 hours after administration.
Results
Pharmacokinetics of rIX-FP in cynomolgus monkeys
Single-dose PK study—Following IV administration to cynomolgus monkeys, the
single-dose pharmacokinetics of rIX-FP were linear over the dose range 50–100 IU kg−1,
and independent of sex (Fig. 1); individual terminal t½ range was 39.8–44.4 hours (mean:
42.2 hours) (Table 1). Systemic clearance of rIX-FP (1.26 mL h−1 kg−1) was low relative to
monkey liver and kidney plasma flow (around 1740 mL h−1 kg−1 and 1100 mL h−1 kg−1,
respectively) [18]. Antibodies against human FIX or human albumin were not detected.
Single-dose TK study—rIX-FP plasma concentrations increased with increasing dose
(Table 1). The increases in maximum concentration (Cmax) and AUC were proportional to
rIX-FP dose after single IV administration for doses of 75–500 IU kg−1 and mean terminal
t½ range was 39.8–55.9 hours (Table 1; in selected animals in which blood sampling was
extended to 240 hours, terminal t½ up to 83.4 hours was calculated). Data from this study
revealed that the effect of rIX-FP on terminal t½ or total plasma clearance was independent
of dose. Following the single rIX-FP dose, no apparent immune response against rIX-FP
was observed.
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Pharmacokinetics of rIX-FP in hemophilia B dogs
Observed human FIX antigen plasma Cmax was higher with rIX-FP versus rFIX (Fig. 2;
Table 2). PK analysis revealed that the estimated clearance of rIX-FP (2.41 mL h−1 kg−1)
was more than four times lower than for rFIX (10.35 mL h−1 kg−1) (Table 2). Accordingly,
the AUC was more than four times higher with rIX-FP versus rFIX (41.5 vs. 9.7 h·IU mL−1,
respectively). Time until levels of human FIX reached values below 0.05 IU mL−1 (the
suggested protective level in patients with hemophilia B) was more than three times longer
with rIX-FP versus rFIX (7.3 days vs. 2.3 days, respectively) (Fig. 3A; Table 2). Moreover,
rIX-FP had a longer terminal t½ and a higher recovery rate than rFIX (51.9 hours vs. 33.6
hours, respectively, for terminal t½ and 43% vs. 23%, respectively, for recovery; Table 2).
The PK evaluation of human FIX activity levels confirmed the improved PK profile of rIX-
FP versus rFIX (Fig. 2; Table 3). While estimated clearance of rIX-FP (0.84 mL h−1 kg−1)
was more than five times lower than for rFIX (4.5 mL h−1 kg−1), terminal t½ was prolonged
around 2.3-fold (i.e., 55.2 hours vs. 23.5 hours, respectively) (Table 3).
Antibodies against human FIX (and against human albumin around the same time [rIX-FP])
were identified in rIX-FP-treated and rFIX-treated animals approximately 10 and 14 days
after drug administration, respectively. Guided by the results from an initial inhibitor
screening assay (an aPTT “mixing” assay; data not shown), the Bethesda inhibitor assay was
performed on selected blood samples that indicated the presence of an inhibitor. Resulting
Bethesda units ranged from 0.99 to 7.04 on day 15 (rIX-FP) and 2.97 to 14.8 on day 22
(rFIX). Since the immune response seen in both groups most likely affected plasma levels
prior to the above-mentioned time points, PK analysis was only completed up to 168 hours
after drug administration.
Duration of correction of prolonged aPTT by rIX-FP and rFIX in hemophilia B dogs
In hemophilia B dogs, aPTT values decreased following study drug administration in both
groups. A return to pre-treatment aPTT values (mean: 97 seconds) was observed following
clearance of the study drugs from the circulation. However, aPTT values remained at the
lower level (below 60 seconds) approximately four times longer with rIX-FP versus rFIX
(5.9 days vs. 1.5 days, respectively), demonstrating a sustained PD effect (Fig. 3B).
Tolerability in cynomolgus monkeys and hemophilia B dogs
A single IV administration of rIX-FP was well tolerated in cynomolgus monkeys at the
doses studied (50–500 IU kg−1) with no toxicologically relevant findings. In hemophilia B
dogs, two animals (one treated with rIX-FP and one with rFIX) experienced a clinical bleed
(i.e., a hematoma). As neither animal ultimately responded to medical treatment (application
of normal canine plasma), both were euthanized 21 days after dosing following concerns
over animal welfare. Since the appearance of inhibitory anti-drug antibodies could be
confirmed in these animals, cross-reactivity of these neutralizing antibodies against the
canine FIX accounted for this non-responsiveness of the treatment with normal canine
plasma. There were no further drop outs in this study. In the remaining animals, no drug-
related clinical signs were recorded following treatment with rIX-FP or rFIX. Furthermore,
white blood cell, hemoglobin, hematocrit and platelet levels were not affected by rIX-FP
treatment (Table 4), and no drug-related changes in clinical chemistry parameters were
found.
Discussion
These studies were performed to further explore the preclinical PK/PD characteristics and
tolerability of rIX-FP in a) hemophilia B dogs, which are deficient in endogenous FIX and,
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b) cynomolgus monkeys with normal endogenous FIX levels. In both cynomolgus monkeys
and hemophilia B dogs, rIX-FP had a favorable PK profile. A mean terminal t½ of 39.8–55.9
hours was calculated in cynomolgus monkeys for the dose range evaluated (50–500 IU
kg−1); whereas in hemophilia B dogs, a mean terminal t½ of 51.9 hours (FIX antigen levels)
and 55.2 hours (FIX activity levels) was calculated after a single IV dose of 100 IU kg−1.
Comparing different dose levels, pharmacokinetics of rIX-FP were linear in cynomolgus
monkeys up to 500 IU kg−1, and independent of sex. In hemophilia B dogs, a higher
recovery rate and a lower clearance rate were seen with rIX-FP versus rFIX, therefore
prolonging the time at which FIX levels were above 0.05 IU mL−1 (the suggested protective
level for patients with hemophilia B). Furthermore, aPTT values remained at a lower level
for approximately four times longer with rIX-FP versus rFIX, demonstrating a sustained PD
effect.
A previous study examined the PK/PD characteristics of 200 IU kg−1 rFIX following a
single IV bolus in cynomolgus monkeys [19]. Evaluation of these data revealed a Cmax of
1.98 IU mL−1, which is lower than the values reported here for 150 IU kg−1 rIX-FP (Cmax
2.18–2.6 IU mL−1). Furthermore, McCarthy et al. reported a terminal t½ of 12.7 ± 1.8 hours
for rFIX [19], versus 39.8–55.9 hours for rIX-FP in our study. These results indicate that
linking recombinant human FIX to recombinant human albumin prolongs the half-life of this
fusion protein at least three-fold.
Canine models of hemophilia are widely used to test the PK/PD characteristics of anti-
hemophilic replacement products [20]. Brinkhous et al. compared the PK profiles of rFIX
and pdFIX in hemophilia B dogs [21]. Following IV infusions of either product (50 IU
kg−1), the PK parameters of the treatments were similar over the first 24 hours using human
FIX antigen levels for calculations (terminal t½: 22.5 and 22.2 hours; clearance: 8.3 and 7.1
mL h−1 kg−1 for rFIX and pdFIX, respectively). Comparable results regarding terminal t½
(19 [rFIX] and 17.9 [pdFIX] hours) were achieved using FIX activity levels for analyses.
While terminal t½ values of our internal study comparator rFIX are approximately
comparable with published data (23.5 [activity data] and 33.6 [antigen data] hours), analysis
of the rIX-FP data demonstrate that the recombinant albumin fusion protein has a longer
terminal t½ (55.2 [activity] and 51.9 [antigen] hours) and decreased clearance rate (0.84
[activity] and 2.41 [antigen] mL h−1 kg−1) versus rFIX and pdFIX in hemophilia B dogs.
Observed differences in PK values based on activity or antigen FIX levels in our study
might be due to a higher sensitivity of the activity assay versus the antigen assay. However,
although absolute PK values were different using antigen or activity FIX levels for
calculations, the respective relative differences between rIX-FP and rFIX are comparable.
Differences between PK values based on activity or antigen data have also been observed in
another study using rFIX in hemophilia B dogs [19].
Furthermore, data from our study in hemophilia B dogs demonstrated a lower recovery rate
for rFIX than for rIX-FP. Based on FIX antigen levels, mean recovery was 23% for rFIX
and 43% for rIX-FP (Table 2), while mean recovery was 50% for rFIX and 95% for rIX-FP
based on FIX activity data (Table 3). These activity data of rFIX are comparable to
published data showing also reduced human FIX recovery values (44% 15 minutes post-
infusion) following administration of rFIX to hemophilia B dogs (100 IU kg−1; IV) [21].
Interestingly, a lower recovery rate was also reported for rFIX versus pdFIX in hemophilia
B patients [3,22]. Possible mechanisms to explain the differences in recovery rate include
intra- and extravascular binding, endothelial cell binding, and post-translational modification
of specific amino acids [9,23–25].
No immune response was seen in cynomolgus monkeys under the study conditions with an
observation period of up to 19 days. However, it has to be mentioned that these animals
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were immunologically tolerant against cynomolgus FIX (and cynomolgus albumin) and only
received a single IV application of rIX-FP. In hemophilia B dogs, anti-human FIX
antibodies (and anti-human albumin antibodies [rIX-FP]) were identified around 10–14 days
following a single dose of rIX-FP or rFIX. Apparently, these anti-drug antibodies had a
neutralizing effect, influencing the PK/PD parameters of the recombinant proteins.
Furthermore, the neutralizing properties of these antibodies could be confirmed by the
Bethesda inhibitor assay. The presence of neutralizing anti-human FIX antibodies was also
reported in a study with hemophilia B dogs following treatment with rFIX or pdFIX [21].
Taken together, hemophilia B dogs seem to be particularly immunologically reactive
towards various pd and rFIX preparations. Moreover, this reactivity most likely contributed
to the differences in estimated PK values of rIX-FP between cynomolgus monkeys and
hemophilia B dogs.
Besides rIX-FP, other FIX products are in development demonstrating extended half-lives in
various animal species (e.g., N9-GP: 41 hours [FIX-deficient mouse], 76 hours [minipig]
and 156 hours [hemophilia B dog] [8]; rFIXFc: 46 hours [FIX-deficient mouse], 35 hours
[rat], 48 hours [hemophilia B dog] and 47 hours [cynomolgus monkey] [9]), and each
product has a specific mode of half-life extension [26–28]. For rIX-FP, an albumin-mediated
active recycling mechanism via the FcRn receptor has been suggested. In addition, using
albumin as a genetic fusion partner has several further advantages, including a lack of
intrinsic activity and the natural abundance of albumin in blood, potentially preventing
problems with tolerability. Furthermore, due to the cleavable linker within rIX-FP, the
albumin moiety is completely removed during activation of the FIX molecule, leaving an
active clotting factor closely resembling the native activated human FIX.
Experiences with half-life extended molecules in hemophilia B dogs and cynomolgus
monkeys suggest that animal PK data are predictive of a longer half-life in humans
[7,8,11,29]. For example, whilst an albumin/interferon-α fusion protein was shown to have
an enhanced PK profile versus interferon-α in cynomolgus monkeys [11], subsequent
studies in patients with chronic hepatitis C confirmed the favorable PK properties [29]. A
phase I trial to investigate the safety of rIX-FP and to confirm the enhanced PK profile of
rIX-FP in patients with hemophilia B has been completed (clinicaltrials.gov;
NCT01233440). Furthermore, a phase I/II trial to assess the pharmacokinetics, safety and
efficacy of rIX-FP in patients with hemophilia B is currently ongoing (NCT01361126). If
the results of the presented rIX-FP study in cynomolgus monkeys and hemophilia B dogs
would directly translate to hemophilia B patients, a once-weekly prophylactic dosing
regimen could be expected.
Conclusion
The presented data reveal that rIX-FP, with its cleavable linker, has a favorable PK profile
with reduced clearance and extended half-life versus pdFIX and rFIX products, respectively,
in cynomolgus monkeys and hemophilia B dogs. Furthermore, rIX-FP treatment was well
tolerated and demonstrated a sustained PD effect. These data support and add to the existing
preclinical PK/PD literature on rIX-FP. Ongoing clinical studies will show whether the
observed improved kinetics translate into a significant half-life extension in patients with
hemophilia B.
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Fig. 1. Observed and fitted human FIX antigen plasma levels in male and female cynomolgus
monkeys treated once with rIX-FP (intravenously)
(A) and (B) 50 IU kg−1; (C) and (D) 100 IU kg−1 (A/C = male, B/D = female). Curves were
fitted according to a two-compartment model plus an endogenous background level
(baseline).
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Fig. 2. Observed and fitted human FIX activity and antigen plasma levels of hemophilia B dogs
treated once with rIX-FP or recombinant factor IX (rFIX) (100 IU kg−1; intravenously)
(A), (C) and (E) rIX-FP; (B) and (D) rFIX. Curves were fitted according to a two-
compartment model (including a background signal for activity data).
Nolte et al. Page 11













Fig. 3. Pharmacokinetic and pharmacodynamic profile of single-dose rIX-FP versus
recombinant factor IX (rFIX) (100 IU kg−1; intravenously) in hemophilia B dogs
(A) Human FIX antigen plasma levels of an average hemophilia B dog, whose central
compartment volume, initial and terminal elimination half-lives, and clearance were the
geometric mean of the individual parameter values. (B) Average activated partial
thromboplastin time (aPTT) values of hemophilia B dogs after baseline and smoothing
spline curve.
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